Weight LossNCT06843512
Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication
An observational study of Weight Loss and Food Selection, run by Penn State University at 1 site in United States.
Trial summary
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Weight Loss, Food Selection
- What is being tested?
- GLP-1 Medication Initiation
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jul 2025to Dec 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be identified from a list of medical patients prescribed GLP-1 medication by their physicians (located in offices near State College or Hershey, PA) and who volunteered to be contacted regarding studies they are eligible for.
Who may be able to join
- Adults (18+) with overweight or obesity (BMI >25 kg/m2)
- Not currently taking an incretin-based medication at baseline
- Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
- Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
- Fluent in English
Who cannot join
- Adults (18+) without overweight or obesity
- <18 years of age at time of testing
- Adults not taking a GLP-1 Medication
- Adults taking a compound GLP-1
- Adults on GLP-1 medication for longer than 2 weeks at baseline
- Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
- Not fluent in English
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University
State College, Pennsylvania, 16802
Christina M Blackmon, 425-499-8049, cmb8633@psu.edu
About this study
Official title: Exploring the Influence of GLP-1 Medication on Food Attitudes and Selection in a Virtual Reality Buffet
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.
- Conditions
- Weight Loss, Food Selection
- Being tested
- GLP-1 Medication Initiation
- Keywords
- GLP-1, Weight Loss, Virtual Reality, Food behavior
- Medical subject headings
- Weight Loss, Food Preferences
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLP-1 Medication InitiationOther
One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Total Weight of Food Selected in the VR Buffet at 3 Months
Measured: Baseline and 3 months
Change from Baseline in Total Calories of Food Selected in the VR Buffet at 3 Months
Measured: Baseline and 3 months
Change from Baseline in Energy Density of Food Selected in the VR Buffet at 3 Months
Measured: Baseline and 3 months
Change from Baseline in Variety of Food Selected in the VR Buffet at 3 Months
Measured: Baseline and 3 months
Secondary outcomes (6)
Change in Baseline Weight Watchers Food Noise Score at 3 Months
Based on participant's answers to the WW Food Noise questionnaire; Scale of 1-5, 1 being strongly disagree and 5 being strongly agree; Higher scores mean more food noise
Measured: Baseline and 3 months
Change in Baseline 9-question External Food Cue Responsiveness Questionnaire Score at 3 Months
Answers are on a 1-4 scale with 1 being "Rarely" and 4 being "A lot"; higher scores suggest more external food cue reactivity
Measured: Baseline and 3 months
Change in Baseline Adult Eating Behavior Score at 3 Months
Answers on a 1-5 scale with 1 being "Strongly disagree" and 5 being "Strongly agree"; 8 subscales, high scores indicate greater expression of subscale measure
Measured: Baseline and 3 months
Change in Baseline Three-Factor Eating Questionnaire Score at 3 Months
Rated on a scale of 1-4 with 1 being "Definitely false" and 4 being "Definitely true"; 3 subscales, higher scales on each means greater expression of that behavior
Measured: Baseline and 3 months
Change in Baseline General Food Craving-Trait Scale Score at 3 Months
Rated on a 0-5 scale with 0 being "Never/not applicable" and 5 being "Always"; higher scores mean more food dependent
Measured: Baseline and 3 months
Change in Baseline Buffet Food Liking Scores at 3 Months
Rated on a 0-100 scale with 0 being "Dislike extremely" and 100 being "Like extremely"; high scores mean greater liking of the food
Measured: Baseline and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2025
- Study start15 Jul 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Weight LossStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Penn State University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Travis Masterson, Penn State University
- Investigators
- Travis Masterson, Principal investigator, The Pennsylvania State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06843512
- Sponsor's protocol ID
- STUDY00026642
- Status last verified
- Sep 2025
- First submitted
- 20 Feb 2025
- Last updated
- 10 Sep 2025
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No